Chronos Therapeutics Limited

With a rapidly increasing ageing population, age-related health problems (including neurological disorders such as Alzheimer’s disease and Parkinson’s disease) are presenting a challenge to, and burden on existing health care provision. Yet whilst such diseases represent a growing therapeutic need, their treatment is hampered both by the cost and time com...

Chronos are exploring the feasibility of developing a fluorescent based worm behavioural model in order to identify compounds with potential uses in neurodegenerative disorders

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no blood-based diagnostic or prognostic test available. The current management of ALS is supportive, palliative, and multidisciplinary with the only approved therapy, riluzole, having a modest efficacy. Recent late stage clinical failures are thought in part to be due to the exi...

Chronos Therapeutics is intending to develop a novel sublingual formulation of RDC5 for patients with amyotrophic lateral sclerosis.

Chronos Therapeutics Ltd, a company spun out of The University of Oxford, has received a grant to study its lead compound RDC5 in the motor neurone disease: Amyotrophic Lateral Sclerosis or ALS. RDC5 has shown very promising results in the company's ChronoscreenTM and in their models of other diseases involving accelerated cell death and neurodegeneration...